Rashmika Potdar

Clinical trials

• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

  Site PI · Recruiting · Phase 3

  Alliance for Clinical Trials in Oncology

  2025–2037
• Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  Site PI · Recruiting · Phase 3

  National Cancer Institute (NCI)

  2024–2039
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  Site PI · Recruiting · Phase 3

  NRG Oncology

  2023–2034
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

  Site PI · Recruiting · Phase 3

  SWOG Cancer Research Network

  2023–2033